Goal
Treat or prevent cancer
Problem
Cancer cells and tumors (blood-related and solid cancers)
Concept Summary
A water-based extract of Taraxacum (dandelion) root induces apoptosis selectively in cancer cells while sparing healthy cells. The extract has shown activity against several human cancer cell lines and in mouse xenograft models, and is currently being evaluated in a Phase 1 clinical trial for refractory hematologic malignancies.
Principles
- Induction of apoptosis
- Selective cytotoxicity toward cancer cells
- Phytochemical activity
Scientific Domains
Materials
- Dandelion root (Taraxacum spp.)
- Water
- Solvent (e.g., ethanol)
Mechanisms of Action
- Activation of intracellular death programs (caspase cascade)
- Selective targeting of cancer-specific pathways
Applications
- Cancer treatment
- Cancer prevention
Claimed Performance
Effective against human T-cell leukemia, chronic myelomonocytic leukemia, pancreatic and colon cancers in vitro and in mouse models; no toxicity to non-cancer cells; undergoing Phase 1 clinical trials to determine safe dose and preliminary efficacy.
Experimental Evidence
In-vitro studies demonstrated apoptosis in multiple cancer cell lines; mouse xenograft studies showed tumor reduction without harming normal tissue; a Phase 1 clinical trial with 30 refractory hematologic cancer patients is enrolling to assess safety, dose-limiting toxicity, and early anti-tumor activity.
Replication Status
In progress - Phase 1 clinical trial ongoing; pre-clinical results have been reproduced in independent animal studies.
Limitations
- Limited clinical data (Phase 1 only)
- Active constituents not fully identified
- Potential variability in extract composition
Red Flags
- Use of promotional language (e.g., "astonishing results") without peer-reviewed publications
- Potential over-statement of efficacy before robust clinical evidence
